Consolidated Balance Sheets - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 11,437,118	$ 22,604,481
Supplies for clinical trials	1,186,186	1,158,632
Other assets	791,485	797,425
Total current assets	13,414,789	24,560,538
Property and equipment, net	109,823	180,922
Supplies for clinical trials	1,309,648	1,115,657
Deposits	1,955,514	4,176,280
Deferred financing costs	100,216	48,977
Total assets	16,889,990	30,082,374
Current liabilities:
Accounts payable	1,342,126	1,161,258
Accrued compensation and benefits	1,109,864	790,487
Accrued liabilities	786,953	317,653
Total current liabilities	3,238,943	2,269,398
CIRM liability	6,945,741	4,133,905
Warrant Liability	573,560	1,958,775
Total liabilities	10,758,244	8,362,078
Commitments and contingencies (Note 5)
Shareholders’ equity:
Preferred stock $0.0001 par value, 1,000,000 shares authorized; 0 shares outstanding as of December 31, 2016 and December 31, 2015	0	0
Common stock, $0.0001 par value; 25,000,000 shares authorized as of December 31, 2016 and 2015 respectively; 3,444,859 and 2,257,718 shares issued and outstanding as of December 31, 2016 and December 31, 2015, respectively	344	225
Additional paid-in capital	102,354,844	95,857,811
Accumulated deficit	(96,223,442)	(74,137,740)
Total shareholders’ equity	6,131,746	21,720,296
Total liabilities and shareholders’ equity	$ 16,889,990	$ 30,082,374